Wilcox R G, Roland J M, Banks D C, Hampton J R, Mitchell J R
Br Med J. 1980 Mar 29;280(6218):885-8. doi: 10.1136/bmj.280.6218.885.
The value of beta-blockade for suspected acute myocardial infarction was assessed by determining the six-week and one-year mortality rates in patients started on propranolol, atenolol, or placebo immediately on entry to a coronary care unit. A total of 388 patients entered this double-blind, randomised study, and when analysed on the basis of the initial, intention-to-treat categories there was no significant difference between the three groups in respect of the mortality rate at one year. There was, however, a high withdrawal rate from the trial; the reasons for this illustrate problems of physician compliance and interpretation of data, which are common to all early-entry trials of haemodynamically active agents in acute myocardial infarction.
通过测定进入冠心病监护病房后立即开始服用普萘洛尔、阿替洛尔或安慰剂的患者的六周和一年死亡率，评估β受体阻滞剂对疑似急性心肌梗死的价值。共有388名患者进入了这项双盲随机研究，根据最初的意向性治疗类别进行分析时，三组在一年死亡率方面没有显著差异。然而，该试验的退出率很高；其原因说明了医生依从性和数据解读方面的问题，这些问题在所有急性心肌梗死血流动力学活性药物的早期进入试验中都很常见。
